Loeb's Third Point Boosts Stake in CV Therapeutics (CVTX) to 9.9%

In a 13D filing on CV Therapeutics, Inc. (Nasdaq: CVTX), Daniel Loeb's Third Point LLC disclosed a 9.9% stake (5.9 million shares) in the company.

In a pretty standard disclosure, Loeb's firm noted that they presently do not have any plans or proposals that relate to or would result in any of the actions required to be described in Item 4 of Schedule 13D.

Yesterday, we noted that Loeb was building the new stake. Link